Viewing StudyNCT03093116



Ignite Creation Date: 2024-05-06 @ 9:52 AM
Last Modification Date: 2024-10-26 @ 12:20 PM
Study NCT ID: NCT03093116
Status: RECRUITING
Last Update Posted: 2024-02-07
First Post: 2017-03-06

Brief Title: A Study of Repotrectinib TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK ROS1 or NTRK1-3 Rearrangements
Sponsor: Turning Point Therapeutics Inc
Organization: Turning Point Therapeutics Inc

Conditions & Keywords Data

Conditions:
Name
Locally Advanced Solid Tumors
Metastatic Solid Tumors
Keywords:
Name View
Advanced Solid Malignancies View
ALK View
ROS1 View
NTRK View
Sarcoma View
Lung Neoplasms View
Carcinoma NSCL View
NSCLC View
Non Small Cell Lung View
Thyroid Disease View
Colonic Neoplasms View
Thyroid Neoplasms View
Carcinoma Neuroendocrine View
Respiratory Tract Neoplasms View
Thoracic Neoplasms View
Neoplasms by Site View
Neoplasms View
Lung Disease View
Respiratory Tract Disease View
Carcinoma Bronchogenic View
Bronchial Neoplasms View
Endocrine System Disease View
Colorectol Neoplasms View
Intestinal Neoplasms View
Gastrointestinal Neoplasms View
Digestive System Neoplasms View
Gastrointestinal Disease View
Colonic Disease View
Intestinal Disease View
Endocrine Gland Neoplasms View
Head and Neck Neoplasms View
Neuroendocrine Tumors View
Neuroectodermal Tumors View
Neoplasms Germ Cell and Embryonal View
Neoplasms by Histologic Type View
Adenocarcinoma View
Non Small Cell Lung Cancer View
Solid Tumors View
Rearrangements View
TRIDENT-1 View
TKI View
TKI naive View
TKI pretreated View
Anti-tumor activity View
Repotrectinib View